Aug 6, 2026 · 18 min · 10 segments
This week's episode covers some updates in small cell lung cancer, chemotherapy-induced nausea/vomiting (CINV), SC administration of isatuximab, and Lu-177 vipivotide tetraxetan. Download the Oncology…
John BazarHost
got to circle back on something I kind of dismissed a few podcasts ago, and that was the approval of subcutaneous izotuximab.
So it's a bit late to the party, and kind of a me-too drug, and so it was approved for the subcutaneous administration.
I honestly just skipped it, I just saw it, I didn't read anything else about it, and I assumed...
And what happens when you assume, I assume that this was a co-formulation with hyaluronase or berhyaluronase.
One way, is via subcutaneous infusion, somewhat similar to what you do for a tizolizumab given sub-Q.
Then there's like a safety tab that you have to pull, like a fire extinguisher, you gotta pull that tab.
And then you gotta push a button, right? Now, every time there's a step, there's a chance for an error.
So, you know, the brand name of this is Sarclisa Exgena is the product for sub-Q administration.
So as you review that for addition to formulary and things like that, there is, you know, probably a large education component needed for the delivery.
And there are two ways to deliver it subcutaneously, which is another potential source of confusion.
got to circle back on something I kind of dismissed a few podcasts ago, and that was the approval of subcutaneous izotuximab.
So it's a bit late to the party, and kind of a me-too drug, and so it was approved for the subcutaneous administration.
I honestly just skipped it, I just saw it, I didn't read anything else about it, and I assumed...
And what happens when you assume, I assume that this was a co-formulation with hyaluronase or berhyaluronase.
One way, is via subcutaneous infusion, somewhat similar to what you do for a tizolizumab given sub-Q.
Then there's like a safety tab that you have to pull, like a fire extinguisher, you gotta pull that tab.
And then you gotta push a button, right? Now, every time there's a step, there's a chance for an error.
So, you know, the brand name of this is Sarclisa Exgena is the product for sub-Q administration.
So as you review that for addition to formulary and things like that, there is, you know, probably a large education component needed for the delivery.
And there are two ways to deliver it subcutaneously, which is another potential source of confusion.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
